Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ. [electronic resource]
Producer: 20200505Description: 117557 p. digitalISSN:- 1879-0631
- Animals
- Behavior, Animal
- Comorbidity
- Diabetes Mellitus, Experimental -- drug therapy
- Diabetic Neuropathies -- drug therapy
- Diet, High-Fat
- Hyperalgesia
- Inflammation -- drug therapy
- Interleukin-1beta -- metabolism
- Male
- NAV1.7 Voltage-Gated Sodium Channel -- metabolism
- Neuroprotective Agents -- therapeutic use
- PPAR gamma -- metabolism
- Pioglitazone -- therapeutic use
- Ranolazine -- therapeutic use
- Rats
- Rats, Wistar
- Spinal Cord -- metabolism
- Tumor Necrosis Factor-alpha -- metabolism
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.